Security data exchange agreements play a crucial role in pharmacovigilance systems in all areas of collection, security, evaluation and reporting. It ensures full compliance with the law and contributes to compliance with pharmacovigilance obligations by preventing duplication of different partners through pharmacovigilance. Yes, yes. SDEAs may be requested in the United States for inspection in accordance with EU drug safety legislation and equivalent FDA legislation. They must be drawn up within a specified time frame and, within the EU, they must contain a specific list of key details, such as. B as the details of the qualified person, etc. Our team establishes robust and reliable agreements to ensure that there is a mechanism to obtain the correct data within a mandatory and compliant time frame to ensure that all activities that take place throughout the transit process comply with the rules applicable to them. For a consultation on the SDEAs, please contact the team with confidence on (0)1483 307920; Alternatively, you may prefer an email With these considerations, the exchange of security data plays a central role in all areas of security data collection, analysis and communication in a specific pharmacovigilance system. They also ensure that the party concerned has all the necessary safety data for the product concerned and help counterparties and the MAH to effectively meet their pharmacovigilance obligations. It is the primary responsibility of the marketing authorization holder to have an ADES to monitor and ensure that no security data falls because of any “gap”. It is imperative that all data get through, and there is a system of acknowledgment and coordination of data sent and received. This applies to both clinical and post-marketing trial situations as well as specific programs such as patient assistance programs. Some companies only want MedWatch or CIOMS I forms for each case, others also source documents.

The legal department is the natural ally of drug safety for SDEAs. It is obviously in the interest of the company to remain in all markets, in accordance with laws and regulations, and the legal department is there to guarantee it. While many lawyers are not familiar with the regulatory requirements for safety reporting, I have experience that they are willing to assist the DS Group in obtaining the appropriate wording in the contracts, helping to prepare the ADES and “forging” the documents to ensure that they are clear and that they cover the necessary points. If necessary, non-serious AEs must be exchanged. In clinical trials, this can only be at the end of the study (although some companies prefer it for signaling). For products marketed in the EU, particularly where some non-serious cases need to be submitted within 90 days in the EU, this may be the case every month or even more often. There should be a database for all ADEDs for all products, partners, dates of agreements, drugs covered, bonds and documents exchanged, etc. In many cases, MAHs do not have sufficient internal resources (specialists or subsidiaries) to deal with photovoltaic activities in all countries where they operate or have their product licenses.

In the event of a shortage of internal resources, legal obligations relating to the safety of the drug may not be met on time and in the rules. It should be remembered once again that, at the end of the day, only the MAH is responsible for complying with legal obligations regarding pharmacovigilance. In such cases, the MAH may hire potential partners. For example, distributors or service providers, for the joint use of pharmacovigilance activities and the full implementation and signature of the DSEA.